Thailand diabetic registry cohort: Predicting death in Thai diabetic patients and causes of death

Journal of the Medical Association of Thailand

Volumn 93, Issue SUPPL 3, 2010, Pages

  Pratipanawatr, Thongchai ^a   Rawdaree, Petch ^b   Chetthakul, Thanya ^c   Bunnag, Pongamorn ^c   Ngarmukos, Chardpraorn ^c   Benjasuratwong, Yupin ^d   Leelawatana, Rattana ^e   Kosachunhanun, Natapong ^f   Plengvidhya, Nattachet ^g   Deerochanawong, Chaicharn ^h   Suwanwalaikorn, Sompongse ⁱ   Krittiyawong, Sirinate ^j   Mongkolsomlit, Sirima ^j   Komoltri, Chulaluk ^f,k  

^a KHON KAEN UNIVERSITY   (Thailand)

^b NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^e PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g CHIANG MAI UNIVERSITY   (Thailand)

^h RANGSIT UNIVERSITY   (Thailand)

ⁱ CHULALONGKORN UNIVERSITY   (Thailand)

^j Theptarin General Hospital   (Thailand)

^k Thumasart University   (Thailand)

more..

Author keywords

Causes of Death; Death rate; Diabetes mellitus; Risk factors of death

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; METFORMIN;

AGED; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; THAILAND;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INFECTION; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; THAILAND;

EID: 79952267889     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
2. Bajaj M, Banerji MA. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep 2004; 4: 213-8.
3. Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S, et al. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care 2003; 26: 2758-63.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
6. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
7. nd ed. Bethesda, MD: National Institute of Health; 1995: 233-58.
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
9. Leelawattana R, Rattarasarn C, Lim A, Soonthornpun S, Setasuban W. Causes of death, incidence and risk factors of cardiovascular diseases in Thai type 2 diabetic patients: a 5 year follow-up study. Diabetes Res Clin Pract 2003; 60: 183-9.
10. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
11. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et al. Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients. J Med Assoc Thai 2006; 89(Suppl 1): S60-5.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
14. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
15. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
16. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
17. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl 1): S12-54.
18. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22: 497-502.
19. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
22. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.